News

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious ...
Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
In a report released today, Mani Foroohar from Leerink Partners maintained a Sell rating on Moderna, with a price target of $18.00. The company’s shares opened today at $28.20. Take advantage of ...
U.S. Health Secretary Robert F. Kennedy Jr. is pulling the plug on $500 million in federal funding for mRNA vaccine ...
In addition to Oppenheimer, Moderna also received a Hold from Citi’s Geoff Meacham in a report issued today. However, on the same day, Bank of America Securities reiterated a Sell rating on Moderna ...
The Department of Health and Human Services will cancel contracts and pull funding for some vaccines that are being developed ...
The US Department of Health and Human Services (HHS) plans to cancel $500m (£376m) in funding for mRNA vaccines being ...
Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...
US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...